Long-term efficacy and safety of raltegravir in the management of HIV infection

Infection and Drug Resistance

Volumn 7, Issue , 2014, Pages 73-84

  Liedtke, Michelle D ^a   Tomlin, C Ryan ^a   Lockhart, Staci M ^a   Miller, Misty M ^a   Rathbun, R Chris ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Antiretroviral; INSTI; Integrase inhibitor; Isentress

Indexed keywords

EFAVIRENZ; ISENTRES; RALTEGRAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; REVIEW; VIRUS LOAD;

EID: 84897829555     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/IDR.S40168     Document Type: Review

References (65)

1. NME drug and new biologic approvals in 2007 [webpage on the Internet]. Silver Spring, MD: US Food and Drug Administration [updated February 10, 2009]. Available from: http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandap-proved/drugandbiologicapprovalreports/ucm081690.htm. Accessed October 31, 2013.
2. US Food and Drug Administration. FDA approves new combination pill for HIV treatment for some patients [press release]. Silver Spring, MD: US Food and Drug Administration; 2012 [August 27; updated August 29, 2012]. Available from: http://www.fda.gov/news-events/newsroom/pressannouncements/ucm317004.htm. Accessed October 31, 2013.
3. US Food and Drug Administration. FDA approves new drug to treat HIV infection [press release]. Silver Spring, MD: US Food and Drug Administration; 2013 [August 12; updated August 13, 2013]. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm364744.htm. Accessed October 31, 2013.
4. US Food and Drug Administration. Isentress (raltegravir) indication extended for the treatment of HIV-1 infection in treatment-naïve patients [press release]. Silver Spring, MD: US Food and Drug Administration [updated July 13, 2009]. Available from: http://www.fda.gov/forconsum-ers/byaudience/forpatientadvocates/hivandaidsactivities/ucm171317.htm. Accessed October 31, 2013.
5. US Food and Drug Administration. FDA expands use of HIV drug Isentress to children and adolescents [press release]. Silver Spring, MD: US Food and Drug Administration; 2011 [December 21]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm284473.htm. Accessed October 31, 2013.
6. Lennox JL, DeJesus E, Lazzarin A; STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692): 796-806.
7. Steigbigel AR, Cooper DA, Kumar PN; BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359(4):339-354.
8. Rockstroh JK, DeJesus E, Lennox JL; STARTMRK Investigators. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defc Syndr. 2013;63(1):77-85.
9. Eron JJ, Cooper DA, Steigbigel RT; BENCHMRK Study Teams. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCH-MRK studies: fnal results of two randomized placebo-controlled trials. Lancet Infect Dis. 2013;13(7):587-596.
10. Summa V, Petrocchi A, Bonelli F, et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem. 2008;51(18): 5843-5855.
11. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008;82(2): 764-774.
12. Johns BA, Kawasuji T, Weatherhead JG, et al. Carbamoyl pyridine HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744). J Med Chem. 2013;56(14): 5901-5916.
13. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov. 2005;4(3):236-248.
14. Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther. 2008;83(2):293-299.
15. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis. 2011;203(9):1204-1214.
16. Wenning L, Anderson M, Petry A, et al. Raltegravir (RAL) dose proportionality and effect of food (abstract H-1046). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA; September 17-20, 2007.
17. Cattaneo D, Gervasoni C, Meraviglia P, et al. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J Antimicrob Chemother. 2012;67(2);460-464.
18. Kassahun M, MacIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007;35(9):1657-1663.
19. Wenning LA, Petry AS, Kost JT, et al. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin Pharmacol Ther. 2009;85(6):623-627.
20. Iwamoto M, Wenning LA, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis. 2008;47(1):137-140.
21. Cattaneo D, Ripamonti D, Baldelli S, Cozzi V, Conti F, Clementi E. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Ther Drug Monit. 2010;32(6): 782-786.
22. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53(7):2852-2856.
23. Iwamoto M, Wenning LA, Petry AS, et al. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2008;52(12):4338-4343.
24. Anderson MS, Kakuda TN, Hanley W, et al. Minimal pharmacoki-netic interaction between the human immunodefciency virus non-nucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother. 2008;52(12):4228-4232.
25. Barrail-Tran A, Yazdanpanah Y, Fagard C, et al. Lack of Interaction between etravirine and raltegravir plus darunavir/ritonavir when combined in treatment-experienced patients: a substudy of the ANRS 139 TRIO trial (abstract 606). 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; February 16-19, 2010.
26. Andrews E, Glue P, Fang J, Crownover P, Tressler R, Damle B. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Br J Clin Pharmacol. 2010;69(1):51-57.
27. Wenning LA, Friedman EJ, Kost JT, et al. Lack of a signifcant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother. 2008;52(9):3253-3258.
28. Hanley WD, Wenning LA, Moreau A, et al. Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53(7):2752-2755.
29. Cooper DA, Steigbigel RT, Gatell JM; BENCHMRK Study Teams. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359(4):355-365.
30. Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis. 2009;48(4):489-492.
31. Rhame F, Matson M, Wood D, et al. Effects of famotidine and omepra-zole on raltegravir pharmacokinetics in HIV infected persons (abstract PE4.1/1). 12th Europeans AIDS Conference; Cologne; November 11-14, 2009.
32. Kiser JJ, Bumpass JB, Meditz AL, et al. Effect of antacids on the pharma-cokinetics of raltegravir in human immunodefciency virus-seronegative volunteers. Antimicrob Agents Chemother. 2010;54(12):4999-5003.
33. Markowitz M, Nguyen B Y, Gotuzzo E; Protocol 004 Part II Study Team. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defc Syndr. 2007;46(2):125-133.
34. Gotuzzo E, Markowitz M, Ratanasuwan W; Protocol 004 Study Team. Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: fnal results of a randomized, controlled, phase II study (Protocol 004). J Acquir Immune Defc Syndr. 2012;61(1):73-77.
35. Raff F, Rachlis A, Stellbrink HJ; SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomized, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735-743.
36. Raff F, Jaeger H, Quiros-Roldan E; Extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomized, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927-935.
37. Young B, Vanig T, DeJesus E; SHIELD Study Team. 96-week results of a pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: the SHIELD trial. HIV Clin Trials. 2011;12(4):228-233.
38. Reynes J, Trinh R, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses. 2013;29(2):256-265.
39. Gatell JM, Katlama C, Grinsztejn B; Protocol 005 Team. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defc Syndr. 2010;53(4):456-463.
40. Grinsztejn B, Nguyen AY, Katlama C; Protocol 005 Team. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369(9569):1261-1269.
41. Elion R, Molina JM, Ramón Arribas López J; Study 145 Team. A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results. J Acquir Immune Defc Syndr. 2013;63(4): 494-497.
42. Capetti A, Landonio S, Meraviglia P, et al. 96 week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicenter Italian experience. PLoS One. 2012;7:e39222.
43. Fagard C, Colin C, Charpentier C; ANRS 139 TRIO Trial Group. Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial. J Acquir Immune Defc Syndr. 2012;59(5):489-493.
44. Nguyen A, Calmy A, Delhumeau C, et al. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER) study. AIDS. 2011;25(12):1481-1487.
45. Gallien S, Braun J, Delaugerre C; EASIER ANRS 138 Study Group. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother. 2011;66(9):2099-2106.
46. Martinez E, Larrousse M, Llibre JM; SPIRAL Study Group. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;24(11): 1697-1707.
47. Eron JJ, Young B, Cooper DA; SWITCHMRK 1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicenter, double-blind, randomized controlled trials. Lancet 2010;375(9712): 396-407.
48. De Castro N, Braun J, Charreau I; EASIER ANRS 138 Study Group. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis. 2009;49(8):1259-1267.
49. Towner W, Klein D, Kerrigan HL, Follansbee S, Yu K, Horberg M. Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. J Acquir Immune Defc Syndr. 2009;51(4): 367-373.
50. Isentress® (raltegravir) [package insert]. Whitehouse Station, NJ: Merck Sharp and Dohme Corp.; 2011.
51. Madeddu G, Menzaghi B, Ricci E; CISAI Group. Raltegravir central nervous system tolerability in clinical practice: results from a multi-center observational study. AIDS. 2012;26(18):2412-2415.
52. Tsai WJ, Lee SS, Tsai HC, et al. Rapid onset of rhabdomyolysis after switching to a raltegravir-based antiretroviral regimen. J Microbiol Immunol Infect. Epub April 20, 2013.
53. Croce F, Vitello P, Dalla Pria A, Riva A, Galli M, Antinori S. Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature. Int J STD AIDS. 2010;21(11):783-785.
54. Lee FJ, Amin J, Bloch M, Pett SL, Marriott D, Carr A. Skeletal muscle toxicity associated with raltegravir-based combination antiret-roviral therapy in HIV-infected adults. J Acquir Immune Defc Syndr. 2013;62(5):525-533.
55. Monteiro P, Perez I, Pich J, Gatell JM, Martinez E. Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study. J Antimicrob Chemother. 2013;68(2):404-408.
56. Isentress (raltegravir potassium) tablet and chewable tablet [webpage on the Internet]. Silver Spring, MD: US Food and Drug Administration; 2013 [updated November 14, 2013]. Available from: http://www.fda.gov/safety/medwatch/safetyinformation/ucm360369.htm. Accessed September 20, 2013.
57. Messiaen P, Wensing AM, Fun A, Nijhuis M, Brusselaers N, Vandekerckhove L. Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis. PLoS One. 2013;8(1):e52562.
58. Saumoy M, Sánchez-Quesada JL, Martínez E, et al. LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy. Atherosclerosis. 2012;225(1):200-207.
59. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services [updated February 12, 2013]. Available from: http://aidsinfo.nih.gov/contentfles/lvguidelines/AdultandAdolescentGL.pdf. Accessed October 10, 2013.
60. Thompson MA, Aberg JA, Hoy J F, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387-402.
61. European AIDS Clinical Society Guidelines. Version 7.0. European AIDS Clinical Society; 2013. Available from https://www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdf. Accessed January 29, 2014.
62. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children [updated November 5, 2012]. Available from: http://aidsinfo.nih.gov/contentfles/lvguidelines/pediatricguidelines.pdf. Accessed October 10, 2013.
63. Eron JJ Jr, Rockstroh JK, Reynes J: QDMRK Investigators. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis. 2011;11(12):907-915.
64. Rizk ML, Hang Y, Luo WL, et al. Pharmacokinetics and pharmacody-namics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother. 2012;56(6): 3101-3106.
65. Tivicay® (dolutegravir) [package insert]. Research Triangle Park, NC: ViiV Healthcare; 2013.